Why do European biotech researchers put AI data mining first for 2030?
An ERC survey of 388 funded researchers ranks AI-enabled life-science data mining above 29 other emerging technologies. It is a useful signal from Europe's research portfolio, not a forecast that AI will deliver clinical or commercial results.
Editorial responsibility: The Impact of AI Editorial Desk · Report a factual concern
Research topic
How ERC-funded biotechnology researchers assess AI-enabled data mining and other emerging technologies through 2030
At a glance
- 1The ERC analysis covers 2,416 biotechnology projects in 28 countries that received €4.09 billion from 2014 to 2023; machine or deep learning appeared in 237 projects.
- 2The May 2026 survey contacted 1,979 project leaders and received 388 responses, a 19.6% response rate; 85% rated AI-enabled life-science data mining likely or very likely to transform biotechnology by 2030.
- 3The result measures expectations among ERC-funded researchers. It does not measure diagnostic accuracy, drug-development success, company revenue or patient outcomes.
Living evidence record
Impact record IAI-1I0IQZ3
Evidence stage
Observed
Confidence
Supported
Reporting basis
Source analysis
Independent support
Not yet
Record status
Monitoring
Last checked
30 September 2026
Source trail
2 direct sources across 2 source types.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Related-source reporting disclosure
This record analyses 2 linked source records around the same underlying development. The extra records add method, date or context, but they do not by themselves constitute independent replication of every performance claim or predicted outcome.
The headline is a research-community expectation, not a technology forecast
The European Research Council's new biotechnology report asks what its funded researchers believe will reshape the field by 2030. AI-enabled life-science data mining ranked first: 85% of survey respondents rated it likely or very likely to have a significant impact, including 59% who selected very likely. That put it ahead of mRNA vaccines at 82%, omics technologies at 78%, tissue engineering at 77% and CRISPR-Cas12 or CRISPR-Cas13 at 76%.
The ranking is informative because it comes from scientists leading frontier-research projects, but it should not be read as a probability that AI will deliver a particular medicine or commercial return. The survey records professional expectations in May 2026. It does not follow products through trials, compare AI-assisted projects with conventional programmes or independently test whether data-mining systems reproduce across laboratories. The correct conclusion is that AI is now embedded in how this research community imagines biotechnology's near future—not that the outcomes are guaranteed.[1][2]
The denominator matters: 388 replies from 1,979 invited researchers
The ERC sent the survey through EUSurvey to all 1,979 grantees leading projects selected for the analysis and received 388 responses, a 19.6% response rate. Respondents rated 30 technologies on a five-point scale, from very likely to highly unlikely, with an additional option for uncertainty. Each technology was rated by 86% to 95% of respondents. Two thirds of respondents came from the ERC life-sciences domain and one third from physical sciences and engineering, broadly matching the wider portfolio; most worked on projects with health applications.
That design gives the findings a defined population and transparent denominator, but non-response remains important. Researchers who see AI as central to biotechnology may have been more motivated to participate, while ERC grantees are not representative of every university, start-up, hospital or country. The 2030 choices were also drawn from OECD and European Commission horizon-scanning work, which makes the list policy-relevant but may frame what respondents considered. Twenty respondents separately raised AI uses in free text, including biological design, foundation models, drug discovery and protein engineering.[1]
AI is already spread through the portfolio rather than confined to an AI category
The wider analysis covers 2,416 ERC biotechnology projects funded between 2014 and 2023 across 28 countries, representing €4.09 billion and 21% of all ERC projects in that period. Machine or deep learning appeared in 237 biotechnology projects, while only 19 were formally classified in the report's AI, Data and ICT sector. The gap suggests AI is often an enabling method inside health, biology or engineering research rather than a standalone research destination. That has practical consequences for funding review, skills and reproducibility: biological teams need data expertise, while model assessment must stay connected to domain evidence.
The report also describes movement towards application, but the pipeline narrows sharply. Biotechnology projects received 531 ERC Proof of Concept grants, and 24 projects went on to receive 25 European Innovation Council Transition grants. Across the portfolio, 211 researchers filed patents and 72 spin-off companies were launched. Those are activity counts, not evidence that the underlying inventions reached patients, scaled manufacturing or produced durable businesses. The ERC itself identifies funding gaps, commercialisation, scale-up, innovation ecosystems and governance as persistent barriers.[1][2]
What institutions can do now—and what would change our assessment
Research institutions can use the finding as a planning signal: improve secure access to life-science data, train mixed biology-and-computing teams, fund independent replication and require clear evaluation against simpler baselines. They should also budget for data stewardship, laboratory validation and regulatory evidence rather than treating model development as the whole innovation pathway. For researchers outside well-funded European networks, shared datasets, open methods and compute access will determine whether AI widens participation or concentrates discovery in a small number of institutions.
Our assessment would strengthen if later studies compare outcomes across AI-intensive and non-AI projects, disclose how many tools progress to laboratory replication, trials or deployment, and reproduce results in less well-resourced regions. It would weaken if the low response rate reflects strong self-selection, if reported AI use remains mostly exploratory or if promising models fail when data sources, laboratories or populations change. The report is a credible map of one major public research portfolio and its researchers' expectations. It is not proof that AI is already the most productive biotechnology investment.[1][2]
What this means for people
- Patients and consumers should not expect immediate new treatments from this ranking; it describes research priorities rather than validated products.
- Researchers may see more funding and skills demand around data stewardship, computational biology and model validation, alongside pressure to demonstrate real-world value.
Global context
The evidence describes an EU-funded portfolio covering 28 countries, with most respondents working on health-related applications. It does not directly represent research priorities in Africa, Asia, Latin America or lower-funded European systems, where data access, compute capacity, regulation and disease burdens may produce different priorities.
What the evidence does not yet show
- The survey response rate was 19.6%, so non-response and enthusiasm bias may affect the ranking of emerging technologies.
- Respondents were ERC-funded project leaders, a highly selected European research population rather than a global sample of scientists, clinicians or companies.
- The report combines portfolio classification, self-reported expectations and innovation indicators; it does not test clinical benefit, commercial success or causal effects of AI use.
What to watch next
- Follow-up evidence linking AI use to reproducible laboratory results, clinical development, manufacturing scale-up or measurable public benefit.
- Replication of the survey in other regions and among researchers who do not hold major frontier-research grants.
- Whether European funding programmes close the transition gap between early research, proof of concept and independently validated deployment.
Evidence trail
Sources used for this report
Links checked 30 September 2026
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Continue the story
Related reporting
Science & Research
Can self-supervised AI help neutrino detectors learn from fewer labelled events?
A Nature Machine Intelligence paper reports strong low-label performance across simulated detector tasks. The million-event dataset is substantial, but it models a proposed detector and cannot substitute for validation on real collisions.
5 min · 2 sources
Science & Research
Can AI make a chemical prediction useful in a different laboratory?
A new Nature Methods publication addresses transfer between chromatography systems. We examine the accessible research record, software and data infrastructure, and propose a practical laboratory test.
6 min · 5 sources
Science & Research
Can AI design better optimisation rules?
A Nature Machine Intelligence paper reports that a structured LLM framework outperformed prior LLM approaches across 36 combinatorial-optimisation benchmarks and produced feasible algorithms for four new port-logistics problems. It remains an offline benchmark, not a live operations result.
8 min · 2 sources
Reader discussion
Add evidence, experience or a question
No account is required. Reader notes are published after a brief civility, relevance and safety check; disagreement is welcome.
Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.